According to reports this morning in the diabetes news, the European Union has now given approval to diabetes drug Eucreas. Novartis, a Swiss pharmaceutical company, submitted the drug for approval and were successful.
The drug, Eucreas, combined Galvus (a recently approved DPP-4 inhibitor) with metformin. The drug is to treat diabetics by increasing insulin sensitivity. Manufacturer Novartis reportedly commented: "The approval comes after Novartis proposed changes to the EU label recommending that liver monitoring should be conducted."
Once the European Medicines Agency has approved a drug, which they did to Eucreas in September, approval usually follows amongst all 27 nations. Galvus, a potential blockbuster diabetes drug for Novartis, has been found to cause liver problems amongst some diabetic patients.
EU approves diabetes drug
Mon, 25 Feb 2008
Join us